Privia Health Group, Inc. $PRVA Shares Purchased by Future Fund LLC

Future Fund LLC boosted its stake in Privia Health Group, Inc. (NASDAQ:PRVA) by 48.0% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 65,538 shares of the company’s stock after acquiring an additional 21,247 shares during the period. Future Fund LLC owned about 0.05% of Privia Health Group worth $1,348,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. Durable Capital Partners LP increased its position in shares of Privia Health Group by 1.8% during the third quarter. Durable Capital Partners LP now owns 11,691,685 shares of the company’s stock worth $291,123,000 after purchasing an additional 203,842 shares in the last quarter. State Street Corp grew its stake in Privia Health Group by 1.5% during the 2nd quarter. State Street Corp now owns 4,171,069 shares of the company’s stock worth $95,935,000 after buying an additional 61,853 shares during the last quarter. Van Berkom & Associates Inc. grew its stake in Privia Health Group by 1.8% during the 4th quarter. Van Berkom & Associates Inc. now owns 3,844,256 shares of the company’s stock worth $91,147,000 after buying an additional 69,691 shares during the last quarter. Geode Capital Management LLC increased its position in Privia Health Group by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 2,814,290 shares of the company’s stock worth $66,738,000 after buying an additional 31,204 shares during the period. Finally, Principal Financial Group Inc. increased its position in Privia Health Group by 1.6% during the fourth quarter. Principal Financial Group Inc. now owns 2,787,802 shares of the company’s stock worth $66,099,000 after buying an additional 43,589 shares during the period. Hedge funds and other institutional investors own 94.48% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on PRVA. Barclays decreased their price objective on Privia Health Group from $25.00 to $24.00 and set an “equal weight” rating for the company in a report on Tuesday, May 26th. Canaccord Genuity Group reduced their price target on shares of Privia Health Group from $35.00 to $34.00 and set a “buy” rating for the company in a research report on Friday, May 8th. Weiss Ratings upgraded shares of Privia Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, July 2nd. Zacks Research downgraded shares of Privia Health Group from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 7th. Finally, Evercore set a $26.00 price objective on shares of Privia Health Group in a research note on Wednesday, April 8th. Eleven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Privia Health Group presently has a consensus rating of “Moderate Buy” and an average price target of $31.15.

Insiders Place Their Bets

In other news, Director Matthew Shawn Morris sold 88,110 shares of the firm’s stock in a transaction on Friday, June 26th. The shares were sold at an average price of $25.33, for a total value of $2,231,826.30. Following the completion of the sale, the director owned 76,651 shares in the company, valued at approximately $1,941,569.83. This trade represents a 53.48% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Parth Mehrotra sold 105,439 shares of Privia Health Group stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $22.55, for a total transaction of $2,377,649.45. Following the completion of the sale, the chief executive officer directly owned 450,004 shares in the company, valued at approximately $10,147,590.20. The trade was a 18.98% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 478,855 shares of company stock worth $12,099,109. 5.70% of the stock is owned by insiders.

Privia Health Group Trading Down 1.2%

NASDAQ:PRVA opened at $26.90 on Friday. The firm has a market cap of $3.39 billion, a P/E ratio of 168.14, a PEG ratio of 2.15 and a beta of 0.83. The stock’s 50 day simple moving average is $24.12 and its 200-day simple moving average is $23.27. Privia Health Group, Inc. has a 12-month low of $18.77 and a 12-month high of $28.82.

Privia Health Group Company Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.